Hangzhou Tigermed Consulting Co., Ltd
OTC: HNGZY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Xiao Chun Cao
- Employees
- 11,130
- Headquarters
- Hangzhou, China
- IPO year
- 2022
- Market cap
- $6.2B
- Website
- https://www.tigermedgrp.com
Loading HNGZY…
Loading profile data…Frequently asked questions about HNGZY
What does Hangzhou Tigermed Consulting Co., Ltd (HNGZY) do?
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacov...
Where does HNGZY trade?
Hangzhou Tigermed Consulting Co., Ltd (HNGZY) trades on the Other OTC.
What sector is HNGZY in?
Hangzhou Tigermed Consulting Co., Ltd (HNGZY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hangzhou Tigermed Consulting Co., Ltd?
Xiao Chun Cao is the chief executive officer of Hangzhou Tigermed Consulting Co., Ltd (HNGZY).
Where is Hangzhou Tigermed Consulting Co., Ltd headquartered?
Hangzhou Tigermed Consulting Co., Ltd is headquartered in China.
Does HNGZY pay a dividend?
Yes — Hangzhou Tigermed Consulting Co., Ltd (HNGZY) paid a trailing twelve-month dividend of USD 0.02 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did HNGZY go public?
Hangzhou Tigermed Consulting Co., Ltd (HNGZY) completed its initial public offering in 2022.